This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Review Article

Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration

Silvana Borges, MD; Yeh-Fong Chen, PhD; Thomas P. Laughren, MD; Robert Temple, MD; Hiren D. Patel, PharmD; Paul A. David, RPh; Mitchell Mathis, MD; Ellis Unger, MD; Peiling Yang, PhD; and Ni A. Khin, MD

Published: March 15, 2014

Article Abstract

Objective: The maintenance efficacy of antidepressants is usually assessed in postmarketing studies with a randomized withdrawal design. This report explores differences in relapse rates, trial characteristics, and success rates in maintenance efficacy studies submitted to the US Food and Drug Administration (FDA) over a 25-year period.

Data Sources: Clinical data from all maintenance trials with antidepressants submitted to FDA between 1987 and 2012.

Study Selection: Efficacy data were compiled from 15 maintenance clinical trials in adults diagnosed with major depressive disorder according to DSM-III or DSM-IV criteria.

Data Extraction: Trial characteristics, relapse rates, and time to relapse in each study were examined.

Results: Relapse rates were significantly lower (P < .05) in the drug arm than in the placebo arm in every study, with a mean relapse rate difference of 18% and an average percent reduction in relapse rate of 52% compared to placebo. Only 6% of the relapse events occurred in the first 2 weeks of the double-blind phase. The separation between treatment arms continued to increase throughout the double-blind phase only in the trial with longest response stabilization period.

Conclusions: Antidepressant maintenance trials have a high rate of success, indicating a benefit of continuing drug treatment after initial response to an antidepressant. This benefit appears to result mainly from a decreased rate of recurrent depression rather than from an effect of drug withdrawal in the placebo groups.

J Clin Psychiatry 2014;75(3):205-214

Submitted: August 7, 2013; accepted November 27, 2013 (doi:10.4088/JCP.13r08722).

Corresponding author: Silvana Borges, MD, Division of Psychiatry Products, HFD-130, Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Rm 4159, Silver Spring, MD 20993-0002 (silvana.borges@fda.hhs.gov).

Volume: 75

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Skeletal and Dental Fractures Associated With Electroconvulsive Therapy

Recent data suggest the risk of skeletal or dental fracture with ECT may be as low as...

Read More...